Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing

被引:10
|
作者
Jaffre, Jeremy [1 ,2 ]
Aubry, Alexandra [1 ,2 ]
Maitre, Thomas [1 ]
Morel, Florence [1 ,2 ]
Brossier, Florence [1 ,2 ]
Robert, Jerome [1 ,2 ]
Sougakoff, Wladimir [1 ,2 ]
Veziris, Nicolas [1 ,2 ,3 ]
机构
[1] Sorbonne Univ, Grp Hosp Univ, Hop Pitie Salpetriere, AP HP,Ctr Natl Reference Mycobacteries & Resistan, Paris, France
[2] Sorbonne Univ, INSERM, Cimi Paris, Ctr Immunol & Malad Infect,U1135, Paris, France
[3] Sorbonne Univ, Grp Hosp Univ, Hop St Antoine, AP HP, Paris, France
关键词
drug susceptibility testing; Mycobacterium avium complex; SLOMYCO Sensititre; Mueller Hinton; clarithromycin; amikacin; IN-VITRO ACTIVITY; RANDOMIZED-TRIAL; LUNG-DISEASE; CLARITHROMYCIN; THERAPY; COMBINATION; ETHAMBUTOL; RIFABUTIN; REGIMENS; AMIKACIN;
D O I
10.3389/fmicb.2020.00081
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand
    Sirichoat, Auttawit
    Kaewprasert, Orawee
    Hinwan, Yothin
    Faksri, Kiatichai
    PLOS ONE, 2023, 18 (11):
  • [22] Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease
    Kadota, Tsukasa
    Matsui, Hirotoshi
    Hirose, Takashi
    Suzuki, Junko
    Saito, Minako
    Akaba, Tomohiro
    Kobayashi, Kouichi
    Akashi, Shunsuke
    Kawashima, Masahiro
    Tamura, Atsuhisa
    Nagai, Hideaki
    Akagawa, Shinobu
    Kobayashi, Nobuyuki
    Ohta, Ken
    BMC INFECTIOUS DISEASES, 2016, 16
  • [23] Genotyping and clarithromycin susceptibility testing of Mycobacterium avium subsp hominissuis isolated in Tuscany, Italy
    Genua, Flavia
    Menichini, Melissa
    Lari, Nicoletta
    Rindi, Laura
    INFECTION GENETICS AND EVOLUTION, 2018, 65 : 144 - 149
  • [24] Treatment of Pulmonary Mycobacterium avium Complex Infections Do Drug Levels Matter?
    Schluger, Neil W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (08) : 710 - 711
  • [25] Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations
    Andrejak, Claire
    Almeida, Deepak V.
    Tyagi, Sandeep
    Converse, Paul J.
    Ammerman, Nicole C.
    Grosset, Jacques H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 2129 - 2135
  • [27] Drug-Drug Interactions of Clinical Significance in the Treatment of Patients with Mycobacterium avium Complex Disease
    Jeffrey J. Kuper
    Michelle D’Aprile
    Clinical Pharmacokinetics, 2000, 39 : 203 - 214
  • [28] Deterioration of Cycloserine in Drug Susceptibility Testing of Mycobacterium
    Wang, Ruibai
    Zhao, Xiuqin
    Wan, Kanglin
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 135 - 140
  • [29] Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system
    Takuya Ozawa
    Ho Namkoong
    Risako Takaya
    Yusuke Takahashi
    Koichi Fukunaga
    Yuki Enoki
    Kazuaki Taguchi
    Junko Kizu
    Kazuaki Matsumoto
    Naoki Hasegawa
    BMC Infectious Diseases, 22
  • [30] Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
    Chu, Jennifer
    Sloan, Caroline E.
    Freedberg, Kenneth A.
    Yazdanpanah, Yazdan
    Losina, Elena
    AIDS RESEARCH AND THERAPY, 2011, 8